Scarica l'app Stockscreener
3.83
6.13%
-0.25
Pre-mercato:
3.86
0.03
+0.78%
Precedente Chiudi:
$4.08
Aprire:
$4.1
Volume 24 ore:
100.04K
Relative Volume:
0.07
Capitalizzazione di mercato:
$20.60M
Reddito:
$15.66M
Utile/perdita netta:
$5.83M
Rapporto P/E:
-0.1603
EPS:
-23.8939
Flusso di cassa netto:
$466.20K
1 W Prestazione:
-15.64%
1M Prestazione:
-20.04%
6M Prestazione:
-43.81%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.83
$4.10
Intervallo di 1 settimana:
$3.83
$4.65
Portata 52W:
$2.90
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Nome
Neuphoria Therapeutics Inc
Settore
Industria
Telefono
781-439-5551
Indirizzo
100 SUMMIT DR, BURLINGTON
Confronta NEUP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.83 | 21.94M | 15.66M | 5.83M | 466.20K | -23.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | Reiterato | Maxim Group | Buy |
| 2022-01-10 | Iniziato | Berenberg | Buy |
| 2022-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-01-10 | Iniziato | Evercore ISI | Outperform |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Neuphoria Therapeutics Inc Borsa (NEUP) Ultime notizie
Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Neuphoria Therapeutics (NASDAQ:NEUP) Cut to Strong Sell at Zacks Research - Defense World
Abeona Therapeutics (NASDAQ:ABEO) and Neuphoria Therapeutics (NASDAQ:NEUP) Critical Comparison - Defense World
Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees - Yahoo Finance
ISS recommends shareholders vote for Neuphoria’s board nominees By Investing.com - Investing.com India
Institutional Shareholder Services Recommends Shareholders of Neuphoria to Vote for its Director Nominees - marketscreener.com
ISS recommends shareholders vote for Neuphoria’s board nominees - Investing.com
Neuphoria Therapeutics (NEUP) Gains ISS Support for Director Nom - GuruFocus
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees - The Manila Times
HC Wainwright Has Lowered Expectations for Neuphoria Therapeutics (NASDAQ:NEUP) Stock Price - Defense World
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA) - The Globe and Mail
Neuphoria Therapeutics (NEUP) Stock Analysis Report | Financials & Insights - Benzinga
HC Wainwright & Co. Maintains Neuphoria Therapeutics (NEUP) Buy Recommendation - Nasdaq
NEUP: Analyst Lowers Price Target by 66% but Maintains 'Buy' Rat - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer By Investing.com - Investing.com Nigeria
Will Neuphoria Therapeutics Inc. stock deliver strong dividend growthIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Neuphoria Therapeutics (NEUP) Considers Strategic Alternatives A - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer - Investing.com
Neuphoria responds to Lynx1's revised indication of interest at a reduced price and premium - marketscreener.com
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium - The Manila Times
Is Neuphoria Therapeutics Inc. stock near bottom after declineEarnings Risk Report & Weekly Top Stock Performers List - Newser
Lynx1 Master Sends a Letter to the Shareholders of Neuphoria Therapeutics - marketscreener.com
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders - Yahoo Finance
Lynx1 Master Fund Critiques Neuphoria Therapeutics Inc. Board's Capital-Raising Strategy and Proposes Independent Director Nominees in Proxy Statement - marketscreener.com
Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program - MSN
Neuphoria responds to Lynx1’s proxy contest claims in board dispute By Investing.com - Investing.com Australia
Neuphoria Therapeutics (NEUP) Encourages Shareholders to Support Its Nominees - GuruFocus
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions - The Manila Times
Neuphoria responds to Lynx1’s proxy contest claims in board dispute - Investing.com
Neuphoria Therapeutics downgraded to Neutral from Buy at Lucid Capital - MSN
Reviewing Neuphoria Therapeutics (NEUP) & The Competition - Defense World
What analysts say about Neuphoria Therapeutics Inc stockMACD Histogram Signals & Discover Your Financial Freedom Formula - earlytimes.in
Sell Signal: How Neuphoria Therapeutics Inc. stock reacts to global recession fearsSwing Trade & Free AI Powered Buy and Sell Recommendations - moha.gov.vn
Lynx1 Capital Management Solicits Proxies from Shareholders of Neuphoria Therapeutics - marketscreener.com
Would You Still Hold Neuphoria Therapeutics Stock If It Fell Another 30%? - Trefis
Neuphoria urges stockholders to vote for its nominees amid strategic review - Investing.com Nigeria
Neuphoria Therapeutics Sends Letter to Stockholders - marketscreener.com
Neuphoria Therapeutics (NEUP) Outlines Strategic Review Ahead of Annual Meeting - GuruFocus
Making the Most of Varied Backgrounds: Ogunbufunmi’s Bold Move Toward Technology Leadership - Bitget
Neuphoria urges stockholders to vote for its nominees amid strategic review By Investing.com - Investing.com South Africa
Neuphoria Therapeutics Inc. Sends Letter to Stockholders - Yahoo Finance
Neuphoria Therapeutics Inc Azioni (NEUP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):